<DOC>
	<DOCNO>NCT00084695</DOCNO>
	<brief_summary>RATIONALE : Umbilical cord blood transplantation may able replace immune cell destroy chemotherapy radiation therapy . PURPOSE : This phase II trial study well umbilical cord blood work source stem cell treat patient type cancer well disease .</brief_summary>
	<brief_title>Umbilical Cord Blood Stem Cell Transplantation Treating Young Patients With Malignant Nonmalignant Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine impact use umbilical cord blood source hematopoietic stem cell child life-threatening oncologic , hematologic , genetic/metabolic disorder need stem cell transplant . - Compare incidence graft-versus-host disease patient receive cord blood transplant study historical data unrelated donor stem cell transplant . - Compare incidence engraftment patient receive cord blood transplant study historical data unrelated donor stem cell transplant . OUTLINE : - Preparative therapy : Patients treat 1 4 preparative therapy regimen . - Regimen A : Patients undergo total body irradiation ( TBI ) two time daily day -7 -4 . Patients receive cyclophosphamide IV 30-60 minute day -3 -2 anti-thymocyte globulin ( ATG ) IV least 6 hour day -3 -1 . - Regimen B ( patient receive TBI ) : Patients receive oral busulfan 4 time daily day -8 -5 , ATG IV least 6 hour melphalan IV 15-20 minute day -4 -2 . - Regimen C ( patient Fanconi 's anemia related disorder ) : Patients undergo TBI day -6 . Patients receive ATG IV least 6 hour methylprednisolone IV day -5 -1 fludarabine IV 30 minute cyclophosphamide IV 30-60 minute day -5 -2 . - Regimen D : Patients receive oral IV busulfan 4 time daily day -9 -5 , ATG IV least 6 hour day -5 -3 , cyclophosphamide IV 30-60 minute day -5 -2 . - Cord blood transplant : All patient undergo umbilical cord blood transplantation day 0 . - Graft-versus-host disease prophylaxis : Patients receive oral IV cyclosporine twice daily begin day -1 . Patients also receive methylprednisolone IV twice daily begin day 5 continue least day 28 . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant nonmalignant disease , include limited following : Acute myeloid leukemia acute lymphoblastic leukemia ( ALL ) resistant disease beyond first clinical remission ( CR ) ALL first CR highrisk 1 follow factor : Hypoploidy Pseudodiploidy translocation ( 9 ; 22 ) , ( 4 ; 11 ) , ( 8 ; 14 ) Elevated WBC diagnosis follow : &gt; 100,000/mm^3 patient 612 month age &gt; 50,000/mm^3 patient 1020 year age &gt; 20,000/mm^3 patient 21 year age Burkitt 's lymphoma/leukemia Chronic myelogenous leukemia first chronic phase beyond Juvenile myelomonocytic leukemia Advanced stage relapse lymphoma Advanced stage relapse solid tumor , include follow : Neuroblastoma Ewing 's sarcoma Rhabdomyosarcoma Myelodysplastic syndrome , exclude patient grade 3 4 myelofibrosis Familial erythrophagocytic histiocytosis Histiocytosis unresponsive medical management Inborn error metabolism Langerhans cell histiocytosis unresponsive medical management Immune deficiency , include : Severe combine immune deficiency WiskottAldrich Hemoglobinopathies , include sickle cell disease thalassemia Severe aplastic anemia Fanconi 's anemia Metabolic storage disease Unrelated cord blood donor must HLAidentical OR may mismatch 1 , 2 , 3 HLAloci ( A , B , DR ) No exist HLAidentical relate donor available time transplantation PATIENT CHARACTERISTICS : Age 21 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>Fanconi anemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood Langerhans cell histiocytosis</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>